Christi Shaw, JPM19 (Credit: Jeff Rumans)

#AS­CO21: A week af­ter nab­bing pri­or­i­ty re­view, Kite un­veils the piv­otal da­ta it hopes will lead to a new CAR-T ap­proval

Just less than a year ago, Gilead’s Kite won a land­mark okay for its sec­ond CAR-T ther­a­py, with da­ta that for­mer head of glob­al de­vel­op­ment Ken Takeshi­ta hailed as “bet­ter than Yescar­ta.” Now, ahead of #AS­CO21, Kite is un­veil­ing piv­otal da­ta to back the drug in a new type of can­cer.

Of 55 pa­tients who re­ceived Tecar­tus for re­lapsed or re­frac­to­ry B-cell pre­cur­sor acute lym­phoblas­tic leukemia (ALL), 71% saw their signs of can­cer dis­ap­pear, new head of clin­i­cal de­vel­op­ment Frank Neu­mann said. How­ev­er, some still had in­com­plete hema­to­log­ic re­cov­ery (which the com­pa­ny de­fined as com­plete re­sponse with in­com­plete hema­to­log­ic re­cov­ery, or CRi).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.